Evaluation of Dendritic Cell Products Generated for Human Therapy and Post-Treatment Immune Monitoring - - BioPharm International

ADVERTISEMENT

Evaluation of Dendritic Cell Products Generated for Human Therapy and Post-Treatment Immune Monitoring


BioPharm International
Volume 21, Issue 3

ESTABLISHING THE QUALITY OF THERAPEUTIC DC PRODUCTS

The quality of therapeutic DC products has to be assessed before they can be released for clinical use. This is usually accomplished by: first determining the phenotypic characteristics of DCs using multicolor flow cytometry that confirms cell maturity and expression of co-stimulatory and migration-related molecules on DC; and then measuring the DCs' ability to induce antigen-specific CTL from naive peripheral blood mononuclear cells (PBMC) precursors. The latter is difficult to execute because of the requirement for functional T-cell assays (e.g., cytotoxicity or ELISPOT), and for prior IVS with DCs as well as the availability of defined antigens or targets. For this reason, various surrogate methods for measuring DC functions have been introduced, including intercellular adhesion molecule (ICAM) expression, cytokine production, endocytosis of latex beads or mannose receptor expression on the cell surface.25,26 These methods are useful in defining the functional status of DC, but do not provide information relevant to their ability to mediate antigen-specific T-cell responses.

Most current anti-tumor vaccines depend on the use of ex vivo manipulated autologous products, thus representing "personalized" therapy. A DC product generated from cells of one individual is referred to as a DC batch. Patient-to-patient variability in starting material makes it difficult to ensure DC batch uniformity. Inter-batch uniformity would be easier to achieve with normal allogeneic DCs than with autologous DC products. Although "off-the-shelf" allogeneic DC products might be more practical and uniform, the possibility of viral transmission and rapid in vivo clearance of allogeneic cells introduces another set of concerns and regulatory issues. Once a batch of DCs is made and its quality tested, it can be aliquoted into sterile vials, and the cells cryopreserved for multiple vaccinations. However, any further manipulation of the vaccine, such as washing or adjusting cell numbers, will necessitate testing for sterility and endotoxin levels before vaccine delivery. From a practical viewpoint, the same batch of DCs can deliver multiple vaccines provided no additional manipulations of DCs are performed.

Current Standards for Release of Therapeutic Dendritic Cell Products


Table 2. Procedures and assays required to evaluate dendtric cell products generated for therapy
Although there are no widely accepted release criteria for therapeutic DCs, the cells should meet predefined sterility, viability, purity, and stability standards (according to 21 CFR 211) as well as defined phenotypic and functional criteria. Assays used for DC characterization and product release are summarized in Table 2. Current FDA recommendations for release of therapeutic DC products specify sterility, viability, purity, phenotypic characterization, and stability measurements, but no functional assays for Phase 1 and 2 studies (FDA current GTP final rule; 21 CFR 211). A definition of release criteria based on expected results of these assays is made before the implementation of DC production and is adhered to for all DC batches produced by a facility. For example, if DC viability of 80% is defined as a release standard, any DC batch with viability <80% would be rejected. The development of potency assays for DC is encouraged throughout the early-phase clinical trials, but is not a requirement for DC release.

Sterility testing. Sterility testing of DC products requires 14-day incubation and ensures the absence of aerobic or anaerobic microorganisms. Results are not available until after DC administration. Therefore, a Gram stain is performed immediately before DC release for therapy. Negative results from the Gram stain and the availability of the established plan of action necessary in case a contaminated DC product is administered are sufficient criteria for release of DC products. The products also must be mycoplasma free. In this instance, DNA hybridization, or RT-PCR–based assays, which take several hours to complete, are performed instead of 28-day mycoplasma culture assays. Endotoxin levels are measured in the final DC product, which must be endotoxin free. For the mycoplasma and endotoxin assays, medium and cells must be submitted for testing.

Viability, purity, and stability. Viability, measured microscopically by a trypan blue-dye test or flow cytometry, using PI or 7 amino-actinomycin D (7-AAD), is necessary to show that most DCs in culture are alive. Viability measurements are especially useful after freezing and thawing DCs aliquoted for multiple vaccinations. Purity determinations use flow cytometry to evaluate the presence of lymphocytes (CD3+, CD19+ or CD56/16+) and/or monocytes (CD14+) in a DC product. In general, purity of 80% or higher is desirable, although the overall requirement for the purity level still remains to be established and will be dictated by the overall immunopotency of the final product. Stability assays measure DCs' ability to retain viability and activity over time at room temperature or in the cold, as well as possible detrimental effects of freezing and thawing. Stability assays are especially critical when a DC-based product is divided into smaller batches that are cryopreserved to be thawed for administration to patients for multiple dosing over long treatment intervals.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here